On September 30, 2021, Cerba Research and ACT Genomics held the official opening of their joint venture CerbACT Asia. The immuno-oncology center of excellence located in Taipei, Taiwan, combines the strengths of the central lab and specialty lab to offer a comprehensive service for research within the immuno-oncology space. We would like to thank everyone who was present at the ceremony, whether virtual or in person, to celebrate this new venture. Below, please find a short recap of the ceremony.
CerbACT Asia Opening Ceremony
Learn more about CerbACT Asia, and how we can support Immuno-Oncology clinical research through PBMC/Cell Isolation, Flow Cytometry (FCM), and Immunohistochemistry (IHC) here: CerbACT Asia – Immuno-Oncology Center of Excellence.
About Cerba Research: Is a leading healthcare company with end-to-end drug development and diagnostic solutions to optimize R&D drug productivity and commercialization. Providing Early phase research, clinical development through central laboratory and diagnostic services, Assay and biomarker development and validation. Working with government agencies, non-government organisations as well as pharma and biotech organisations to change the shape of clinical development.
Cerba Research is part of Cerba HealthCare, a leading player in medical diagnosis.
For more information: www.cerbaresearch.com
About ACT Genomics: Is an innovation-driven cancer solution provider in Asia with offices in Taipei, Hong Kong, Singapore & Tokyo. With our Next-Generation Sequencing (NGS) technology, CAP-accredited laboratories, experienced bioinformatics team and proprietary AI algorithms, we provide optimal cancer treatment planning, immunotherapy evaluation, cancer relapse & drug resistance monitoring, as well as cancer risk assessment services to medical professionals. Together, we “Turn Genomics into Action.”
For more information: www.actgenomics.com